DNA vaccines: progress and challenges.
In the years following the publication of the initial in vivo demonstration of the ability of plasmid DNA to generate protective immune responses, DNA vaccines have entered into a variety of human clinical trials for vaccines against various infectious diseases and for therapies against cancer, and are in development for therapies against autoimmune diseases and allergy. They also have become a widely used laboratory tool for a variety of applications ranging from proteomics to understanding Ag presentation and cross-priming. Despite their rapid and widespread development and the commonplace usage of the term "DNA vaccines," however, the disappointing potency of the DNA vaccines in humans underscores the challenges encountered in the efforts to translate efficacy in preclinical models into clinical realities. This review will provide a brief background of DNA vaccines including the insights gained about the varied immunological mechanisms that play a role in their ability to generate immune responses.
Donnelly
John J
JJ
Chiron Vaccines, Chiron Corporation, Emeryville, CA 94608, USA. john_donnelly@chiron.com
Wahren
Britta
B
Liu
Margaret A
MA
D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D006801:Humans; D019444:Vaccines, DNA / Q000138:chemical synthesis / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use
D019444:Vaccines, DNA